Startup Phrase’s Post

Infosys Invests ₹8 Cr in 4baseCare to Drive AI-Powered Cancer Care 🧬 Nikita Saha writes ✍️ Infosys has invested ₹8 Cr (USD 1 Mn) in healthcare startup 4baseCare through its Innovation Fund, advancing AI and analytics-driven precision oncology solutions. Bengaluru-based 4baseCare focuses on personalized cancer treatments using high-tech genomics and digital health technologies. With plans to scale operations across India, Asia, and the Middle East, the startup is setting up genomics labs in Philippines, Nepal, and Dubai to enhance data-driven treatment solutions. This collaboration aligns with Infosys’ strategy to partner with AI and DeepTech startups to transform healthcare innovation and improve patient outcomes. 🔗 Read More – https://lnkd.in/gCJuSfDM 🌐 Stay Updated – https://lnkd.in/gMUPB2Zp #AIInHealthcare #PrecisionOncology #InfosysInnovation #4baseCare #CancerCare #Genomics #HealthcareTech

Toby Health Investor Presentation Meeting Virtually Next Week on TUESDAY AUG 20 at 7PM Central (Message me here on LinkedIn or Shoot me a note if you'd like the link: ron@fractionalcmogroup.com) Toby Has the Potential to Disrupt Cancer Testing ATTN: ACCREDITED INVESTORS: YOU CAN PLAY A PART IN GAME CHANGING HEALTHCARE!! PLEASE READ ON... Toby is revolutionizing early cancer detection to save lives with their urine test and AI technology. Toby offers a potentially revolutionary approach to early cancer detection through a simple urine test. The company is seeking investment to further develop and commercialize their product. HERE'S WHY YOU SHOULD JUMP IN... >> Non-Invasive and Painless: Unlike blood draws or biopsies, Toby's urine test is a simple, painless procedure. >> Early Detection: Toby's potential to detect cancer in its early stages can significantly improve treatment outcomes and survival rates. >> High Accuracy: Toby's test has demonstrated superior accuracy compared to traditional blood tests for certain cancers, such as prostate and kidney cancer. >> Multiple Cancer Detection: Toby's platform is designed to detect multiple cancers with a single urine test, increasing its potential impact. >> Cost-Effective: By detecting cancer earlier, Toby has the potential to reduce overall healthcare costs through early intervention. >> Improved Patient Experience: The convenience and non-invasive nature of the test enhance the overall patient experience. >> Market Potential: The global cancer testing market is vast, offering significant growth opportunities for Toby. >> Technological Innovation: Toby's use of spectroscopy and machine learning represents a patentable cutting-edge approach to cancer detection. >> Strong Leadership: A skilled leadership team, as evidenced by the 42PLUS1 pitch competition win, is in place to drive the company forward. >> Investor Support: Secure investment commitments demonstrate confidence in Toby's potential and future growth. >> Proven Accuracy: Toby’s prostate cancer test boasts a 92% accuracy rate, significantly higher than the traditional PSA test’s 68%. Their kidney cancer test is 94% accurate, with no current alternatives available. >> Investment Opportunity: Toby is raising $3M to begin rolling out their solution. They recently won the DxPx competition, securing a $1M non-dilutive prize, and have $1M soft circled. Be part of this exciting venture! Event Highlights: ·        Networking: Connect with like-minded investors and industry experts. ·        Q&A Session: Get your questions answered by the co-founders. ·        Exclusive Updates: Hear about Toby’s latest achievements and future plans. Don’t miss this opportunity to be at the forefront of cancer detection. Register now and secure your spot on August 20th at 7 PM Central!  RSVP to: ron@fractionalcmogroup.com or len_bland@conceptequity.com and we will provide the ZOOM link to you.

Toby Health Investor Presentation Meeting Virtually Next Week on TUESDAY AUG 20 at 7PM Central (Message me here on LinkedIn or Shoot me a note if you'd like the link: ron@fractionalcmogroup.com) Toby Has the Potential to Disrupt Cancer Testing ATTN: ACCREDITED INVESTORS: YOU CAN PLAY A PART IN GAME CHANGING HEALTHCARE!! PLEASE READ ON... Toby is revolutionizing early cancer detection to save lives with their urine test and AI technology. Toby offers a potentially revolutionary approach to early cancer detection through a simple urine test. The company is seeking investment to further develop and commercialize their product. HERE'S WHY YOU SHOULD JUMP IN... >> Non-Invasive and Painless: Unlike blood draws or biopsies, Toby's urine test is a simple, painless procedure. >> Early Detection: Toby's potential to detect cancer in its early stages can significantly improve treatment outcomes and survival rates. >> High Accuracy: Toby's test has demonstrated superior accuracy compared to traditional blood tests for certain cancers, such as prostate and kidney cancer. >> Multiple Cancer Detection: Toby's platform is designed to detect multiple cancers with a single urine test, increasing its potential impact. >> Cost-Effective: By detecting cancer earlier, Toby has the potential to reduce overall healthcare costs through early intervention. >> Improved Patient Experience: The convenience and non-invasive nature of the test enhance the overall patient experience. >> Market Potential: The global cancer testing market is vast, offering significant growth opportunities for Toby. >> Technological Innovation: Toby's use of spectroscopy and machine learning represents a patentable cutting-edge approach to cancer detection. >> Strong Leadership: A skilled leadership team, as evidenced by the 42PLUS1 pitch competition win, is in place to drive the company forward. >> Investor Support: Secure investment commitments demonstrate confidence in Toby's potential and future growth. >> Proven Accuracy: Toby’s prostate cancer test boasts a 92% accuracy rate, significantly higher than the traditional PSA test’s 68%. Their kidney cancer test is 94% accurate, with no current alternatives available. >> Investment Opportunity: Toby is raising $3M to begin rolling out their solution. They recently won the DxPx competition, securing a $1M non-dilutive prize, and have $1M soft circled. Be part of this exciting venture! Event Highlights: ·        Networking: Connect with like-minded investors and industry experts. ·        Q&A Session: Get your questions answered by the co-founders. ·        Exclusive Updates: Hear about Toby’s latest achievements and future plans. Don’t miss this opportunity to be at the forefront of cancer detection. Register now and secure your spot on August 20th at 7 PM Central!  RSVP to: ron@fractionalcmogroup.com or len_bland@conceptequity.com and we will provide the ZOOM link to you.

Toby Health Investor Presentation Meeting Virtually Next Week on TUESDAY AUG 20 at 7PM Central (Message me here on LinkedIn or Shoot me a note if you'd like the link: ron@fractionalcmogroup.com) Toby Has the Potential to Disrupt Cancer Testing ATTN: ACCREDITED INVESTORS: YOU CAN PLAY A PART IN GAME CHANGING HEALTHCARE!! PLEASE READ ON... Toby is revolutionizing early cancer detection to save lives with their urine test and AI technology. Toby offers a potentially revolutionary approach to early cancer detection through a simple urine test. The company is seeking investment to further develop and commercialize their product. HERE'S WHY YOU SHOULD JUMP IN... >> Non-Invasive and Painless: Unlike blood draws or biopsies, Toby's urine test is a simple, painless procedure. >> Early Detection: Toby's potential to detect cancer in its early stages can significantly improve treatment outcomes and survival rates. >> High Accuracy: Toby's test has demonstrated superior accuracy compared to traditional blood tests for certain cancers, such as prostate and kidney cancer. >> Multiple Cancer Detection: Toby's platform is designed to detect multiple cancers with a single urine test, increasing its potential impact. >> Cost-Effective: By detecting cancer earlier, Toby has the potential to reduce overall healthcare costs through early intervention. >> Improved Patient Experience: The convenience and non-invasive nature of the test enhance the overall patient experience. >> Market Potential: The global cancer testing market is vast, offering significant growth opportunities for Toby. >> Technological Innovation: Toby's use of spectroscopy and machine learning represents a patentable cutting-edge approach to cancer detection. >> Strong Leadership: A skilled leadership team, as evidenced by the 42PLUS1 pitch competition win, is in place to drive the company forward. >> Investor Support: Secure investment commitments demonstrate confidence in Toby's potential and future growth. >> Proven Accuracy: Toby’s prostate cancer test boasts a 92% accuracy rate, significantly higher than the traditional PSA test’s 68%. Their kidney cancer test is 94% accurate, with no current alternatives available. >> Investment Opportunity: Toby is raising $3M to begin rolling out their solution. They recently won the DxPx competition, securing a $1M non-dilutive prize, and have $1M soft circled. Be part of this exciting venture! Event Highlights: ·        Networking: Connect with like-minded investors and industry experts. ·        Q&A Session: Get your questions answered by the co-founders. ·        Exclusive Updates: Hear about Toby’s latest achievements and future plans. Don’t miss this opportunity to be at the forefront of cancer detection. Register now and secure your spot on August 20th at 7 PM Central!  RSVP to: ron@fractionalcmogroup.com or len_bland@conceptequity.com and we will provide the ZOOM link to you. Len Bland Scott Samuel

Toby Health Investor Presentation Meeting Virtually Next Week on TUESDAY AUG 20 at 7PM Central (Message me here on LinkedIn or Shoot me a note if you'd like the link: ron@fractionalcmogroup.com) Toby Has the Potential to Disrupt Cancer Testing ATTN: ACCREDITED INVESTORS: YOU CAN PLAY A PART IN GAME CHANGING HEALTHCARE!! PLEASE READ ON... Toby is revolutionizing early cancer detection to save lives with their urine test and AI technology. Toby offers a potentially revolutionary approach to early cancer detection through a simple urine test. The company is seeking investment to further develop and commercialize their product. HERE'S WHY YOU SHOULD JUMP IN... >> Non-Invasive and Painless: Unlike blood draws or biopsies, Toby's urine test is a simple, painless procedure. >> Early Detection: Toby's potential to detect cancer in its early stages can significantly improve treatment outcomes and survival rates. >> High Accuracy: Toby's test has demonstrated superior accuracy compared to traditional blood tests for certain cancers, such as prostate and kidney cancer. >> Multiple Cancer Detection: Toby's platform is designed to detect multiple cancers with a single urine test, increasing its potential impact. >> Cost-Effective: By detecting cancer earlier, Toby has the potential to reduce overall healthcare costs through early intervention. >> Improved Patient Experience: The convenience and non-invasive nature of the test enhance the overall patient experience. >> Market Potential: The global cancer testing market is vast, offering significant growth opportunities for Toby. >> Technological Innovation: Toby's use of spectroscopy and machine learning represents a patentable cutting-edge approach to cancer detection. >> Strong Leadership: A skilled leadership team, as evidenced by the 42PLUS1 pitch competition win, is in place to drive the company forward. >> Investor Support: Secure investment commitments demonstrate confidence in Toby's potential and future growth. >> Proven Accuracy: Toby’s prostate cancer test boasts a 92% accuracy rate, significantly higher than the traditional PSA test’s 68%. Their kidney cancer test is 94% accurate, with no current alternatives available. >> Investment Opportunity: Toby is raising $3M to begin rolling out their solution. They recently won the DxPx competition, securing a $1M non-dilutive prize, and have $1M soft circled. Be part of this exciting venture! Event Highlights: ·        Networking: Connect with like-minded investors and industry experts. ·        Q&A Session: Get your questions answered by the co-founders. ·        Exclusive Updates: Hear about Toby’s latest achievements and future plans. Don’t miss this opportunity to be at the forefront of cancer detection. Register now and secure your spot on August 20th at 7 PM Central!  RSVP to: ron@fractionalcmogroup.com or len_bland@conceptequity.com and we will provide the ZOOM link to you.

"Over the past five years, oncology health tech companies have raised over $16 billion of venture capital, reaching a peak of $5 billion in 2021. While mortality rates from cancer have declined due to advances in screening and treatment and lower rates of smoking, the number of new cancer cases has remained steady; there has also been a recent, puzzling rise in cancer rates among younger populations. While technological innovations have lowered mortality rates, it is becoming increasingly difficult to reduce death rates further, as much of the low-hanging fruit in cancer care innovation has already been accomplished. Demand for the latest innovations in cancer care technologies should remain strong, and cancer is expected to contribute to overall healthcare costs significantly. Assuming a conservative compound annual growth rate of 4% and a current market size of $250 billion, we expect the oncology health tech market to expand to over $400 billion within the next decade, providing ample opportunity for startups to take share—or find successful exit outcomes—even in a market largely dominated by incumbents." Taken from the recently published Oncology Healthtech VC Market Snapshot by PitchBook. Source: https://lnkd.in/eFsidxBP

🚀 Transforming Cancer Treatment with AI 🚀 Valar Labs, a biotech innovator, has made headlines by raising $22 million to advance their AI-driven cancer care tools. They've created a prediction mechanism that skillfully determines patient responses to treatments, starting with bladder cancer. Imagine cutting down the uncertainty in treatment methodologies and sparing patients unnecessary side effects. 🔍 What It Means for Startups & Small Businesses: - Innovation Inspiration: Valar Labs began with a small, targeted solution and scaled up. This approach can be a blueprint for startups aiming for impact. - Tech Application: Their use of AI in practical, high-stakes environments teaches us about building robust, reliable tech solutions. - Funding Strategy: Securing substantial Series A funding from notable investors like Andreessen Horowitz shows the importance of presenting a scalable business model that addresses a critical pain point. Valar's journey offers valuable lessons in specialty innovation, the importance of precise market fit, and strategic funding. A practical takeaway? Start small, think big! 🧬 Read more about their groundbreaking work at: #HealthTech #Startups #Innovation This post was generated by an AI. Please contact us for more information.

Hitesh Goswami and Kshitij Rishi are on a mission to transform 4baseCare into India’s leading precision oncology company, and their journey is nothing short of remarkable. Precision oncology, at its core, offers hope where traditional cancer treatments often fall short, by tailoring therapies to the unique genetic profile of each patient’s cancer. Their breakthrough work not only improves treatment outcomes but also significantly reduces costs and turnaround times, making advanced cancer care more accessible to millions of Indians. With cancer being among the leading causes of death in the country (second leading in urban India for adults, and the fourth leading cause in rural areas), this work is critical. Today, over 350 of India’s top oncologists rely on 4baseCare's innovative tests to provide targeted treatments that can make a real difference in patient survival and quality of life. The road hasn’t been easy. Hitesh, Kshitij, and their dedicated team have faced immense challenges, yet their resilience and commitment have only strengthened their resolve. I have no doubt that, in the years to come, their contributions will be recognised as pivotal in improving patient outcomes across Asia. A special shoutout to our co-investors, Mount Judi Ventures and Season Two Ventures, whose unwavering support has been crucial during the toughest times. And a warm welcome to Ganapathy Subramaniam, Mathew Cyriac, and the Yali Capital. Your expertise will undoubtedly help 4baseCare overcome every obstacle and achieve its audacious goals. Sheetal Bahl I Ashita Gupta I Dilsher Dhupia I Merak Ventures I growX ventures

🔬 ExSURE PVT. LTD. Secures ₹3 Cr Seed Funding to Revolutionize Cancer Treatment 🚀 Founded in 2021 by Swastika Paul and Abhishek Dutta, Bhubaneswar-based Biotech startup Exsure has raised ₹3 crore in a seed round led by Unicorn India Ventures. Exsure develops a patented exosomal drug-delivery platform to reduce the toxicity and side effects of anti-cancer drugs. Its technology targets both cancer and cancer stem cells, aiming to improve patient outcomes and survival rates. The fresh capital will support non-clinical studies, global expansion, and product promotion, including its innovative R&D solutions like Exosure, Leucosure, PlantExosure, and Dr. Berries. Why Exsure Matters💡 🧬 Revolutionizing Drug Delivery: Exsure’s patented exosomal drug-delivery platform minimizes the toxic effects of chemotherapy while targeting both cancer and cancer stem cells. 🎗️ Reducing Cancer Relapse: By enhancing drug precision, Exsure aims to lower chemotherapy side effects and improve survival rates for cancer patients. 🏆 Global Recognition & Expansion: Exsure has been selected for the OIST Innovation Accelerator Program in Japan to support clinical trials and international growth. 🔬 Cutting-Edge R&D: The startup has launched India’s first plant exosome isolation reagent and is on track to service 50+ clients this year with its innovative R&D solutions. 📈 Rapid Growth: With 5X revenue growth last fiscal year, Exsure is shaping the future of biotech-driven cancer treatment. By pushing the boundaries of biotechnology and drug delivery, Exsure is redefining cancer care and improving patient outcomes. This funding brings it one step closer to making cancer treatment safer and more effective. #ExsureBiotech #CancerTreatment #Biotech #Innovation #StartupNews #Exosome #DrugDelivery #StartupFunding #DeepTechIndia #LifeSciences #OncologyResearch #Healthcare #News #IndianStartups #Technology #AI #Hypes Start Big, Start Here.

🧬ErlySign Secures ₹16 Crore in Pre-Series A Round to Revolutionize Oral Cancer Detection 💰🩺 Founded by Shubhendra Singh Thakur and Deovrat Begde in Nagpur, ErlySign, formerly known as CURO BIOSCIENCES PRIVATE LIMITED, has raised ₹16 crore in a pre-Series A funding round led by investor Ashish Kacholia. ErlySign has developed a salivary biomarker-based test that detects oral precancerous conditions in just 15 minutes. This non-invasive, rapid test helps identify early signs of oral cancer, providing an affordable and pain-free alternative to traditional diagnostic procedures. The funding, guided by Boutique Advisers Private Wealth & DerivativeSaint, will fast-track the development of the startup’s innovative oral cancer detection kit🧬💡 Why ErlySign Matters: 🎯 1) Innovation in Healthcare: ErlySign’s test is quick, affordable, and highly effective, revolutionizing early cancer detection for oral cancer. 💉 2) High Accuracy: The test boasts 100% specificity and 98.04% sensitivity, ensuring a reliable diagnostic tool. ✅🔬 3) Global Potential: With patents secured in India and the U.S., ErlySign is positioned for global expansion, addressing the growing need for accessible cancer testing. 🌍📈 4) Future Growth: Beyond oral cancer, ErlySign plans to leverage CRISPR miRNA-based technology to test for multiple types of cancer from a single saliva sample. 🧬🧪 With strong backing, ErlySign is poised to revolutionize cancer diagnostics, offering a simple, fast, and reliable solution that could save lives by detecting cancer early. The funding will drive R&D and global expansion, improving healthcare access for millions. 🌟🔍 #ErlySign #CancerDetection #HealthcareInnovation #OralCancer #News #AI #EarlyDiagnosis #Diagnostics #CRISPR #HealthCare #Startups #Cancer #IndianStartups #StartupNews #Tech #HealthcareStartups #FundingNews #Hypes Start Big, Start Here.